In order to determine the effects of pravastatin (Pra) on angiogenic and placental hypoxic imbalance in a model of preeclampsia induced by overexpression of soluble fms-like tyrosine kinase 1 (sFlt-1), we randomly allocated pregnant CD1 mice to injection with adenovirus-carrying sFlt-1 or mFc (control). The sFlt-1 group received either Pra (sFlt-1 + Pra) or water (sFlt-1). Mice were sacrificed at day 18, and serum levels of sFlt-1 and soluble endoglin (sEng) were measured. Placental expression of placental (PLGF) and vascular endothelial (VEGF) growth factors and other markers of angiogenesis and hypoxia were assayed. We observed that Pra treatment in sFlt-1 mice reduced sFlt-1 and sEng concentrations at day 18 to levels similar to control group. Placental PLGF and VEGF expression were upregulated, and markers of hypoxia downregulated to levels similar to control group. Hence, Pra prevents the rise in circulating antiangiogenic factors in a mouse model of preeclampsia. Statins may represent a novel approach to prevention of preeclampsia.
ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol. 2002;99(1):159–167.
2.
BartonJRSibaiBM. Prediction and prevention of recurrent preeclampsia. Obstet Gynecol. 2008;112(2 pt 1):359–372.
3.
MakridesMDuleyLOlsenSF.Marine oil, and other prostaglandin precursor, supplementation for pregnancy uncomplicated by pre-eclampsia or intrauterine growth restriction. Cochrane Database Syst Rev. 2006;(3):CD003402.
4.
RobertsJMMyattLSpongCYVitamins C and E to prevent complications of pregnancy-associated hypertension. N Engl J Med. 2010;362(14):1282–1291.
5.
TrumboPREllwoodKC. Supplemental calcium and risk reduction of hypertension, pregnancy-induced hypertension, and preeclampsia: an evidence-based review by the US Food and Drug Administration. Nutr Rev. 2007;65(2):78–87.
6.
XuHPerez-CuevasRXiongXAn international trial of antioxidants in the prevention of preeclampsia (INTAPP). Am J Obstet Gynecol. 2010;202(3):239.e1–239.e10.
7.
LevineRJMaynardSEQianCCirculating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350(7):672–683.
8.
LevineRJLamCQianCSoluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355(10):992–1005.
9.
BerendsALde GrootCJSijbrandsEJShared constitutional risks for maternal vascular-related pregnancy complications and future cardiovascular disease. Hypertension. 2008;51(4):1034–1041.
10.
HanssonGK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–1695.
11.
RedmanCWSargentIL. Latest advances in understanding preeclampsia. Science. 2005;308(5728):1592–1594.
12.
BellamyLCasasJPHingoraniADWilliamsDJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007;335(7627):974.
13.
HarskampREZeemanGG. Preeclampsia: at risk for remote cardiovascular disease. Am J Med Sci. 2007;334(4):291–295.
14.
LykkeJALanghoff-RoosJSibaiBMFunaiEFTricheEWPaidasMJ. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension. 2009;53(6):944–951.
15.
MoscaLBenjaminEJBerraKEffectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: a guideline from the american heart association. Circulation. 2011;123(11):1243–1262.
16.
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339(19):1349–1357.
17.
LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet. 2002;359(9315):1379–1387.
18.
BrugtsJJYetginTHoeksSEThe benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.
19.
MillsEJRachlisBWuPDevereauxPJAroraPPerriD. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52(22):1769–1781.
20.
ShawSMFildesJEYonanNWilliamsSG. Pleiotropic effects and cholesterol-lowering therapy. Cardiology. 2009;112(1):4–12.
21.
ShepherdJCobbeSMFordIPrevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301–1307.
22.
LuFLongoMTamayoEThe effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am J Obstet Gynecol. 2007;196(4):396.e1–396.e7.
23.
MaynardSEMinJYMerchanJExcess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649–658.
24.
CostantineMMTamayoELuFUsing pravastatin to improve the vascular reactivity in a mouse model of soluble fms-like tyrosine kinase-1-induced preeclampsia. Obstet Gynecol. 2010;116(1):114–120.
25.
FoxKALongoMTamayoEEffects of pravastatin on mediators of vascular function in a mouse model of soluble Fms-like tyrosine kinase-1-induced preeclampsia. Am J Obstet Gynecol. 2011;205(4):366 e1–366 e5.
26.
KumasawaKIkawaMKidoyaHPravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci USA. 2011;108(4):1451–1455.
27.
AhmedASinghJKhanYSeshanSVGirardiG. A new mouse model to explore therapies for preeclampsia. PLoS One. 2010;5(10):e13663.
28.
SinghJAhmedAGirardiG. Role of complement component C1q in the onset of preeclampsia in mice. Hypertension. 2011;58(4):716–724.
29.
LivakKJSchmittgenTD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25(4):402–408.
30.
TorryDSMukherjeaDArroyoJTorryRJ. Expression and function of placenta growth factor: implications for abnormal placentation. J Soc Gynecol Investig. 2003;10(4):178–188.
31.
Lopez-NovoaJM. Soluble Endoglin is an accurate predictor and a pathogenic molecule in pre-eclampsia. Nephrol Dial Transplant. 2007;22(3):712–714.
32.
CaniggiaIMostachfiHWinterJHypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3). J Clin Invest. 2000;105(5):577–587.
33.
CaniggiaIGrisaru-GravnoskySKuliszewskyMPostMLyeSJ. Inhibition of TGF-beta 3 restores the invasive capability of extravillous trophoblasts in preeclamptic pregnancies. J Clin Invest. 1999;103(12):1641–1650.
34.
McTaggartFBuckettLDavidsonRPreclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 2001;87(5A):28B–32B.
35.
CudmoreMAhmadSAl-AniBFujisawaTCoxallHChudasamaKDeveyLRWigmoreSJAbbasAHewettPWAhmedA. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation. 2007;115(13):1789–1797.
36.
HazukuANHiraseTIdeNIkedaYNodeK. Simvastatin stimulates vascular endothelial growth factor production by hypoxia-inducible factor 1-α upregulation in endothelial cells. J Cardiovasc Pharmacol. 2008;51(3):267–273.
37.
HatanakaT. Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin Pharmacokinet. 2000;39(6):397–412.
38.
KazminAGarcia-BournissenFKorenG. Risks of statin use during pregnancy: a systematic review. J Obstet Gynaecol Can. 2007;29(11):906–908.
39.
EdisonRMuenkeM. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am J Med Genet A. 2004;131(3):287–298.
40.
OforiBReyEBerardA. Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol. 2007;64(4):496–509.
41.
TaguchiNRubinETHosokawaA. Prenatal exposure to HMG-CoA reductase inhibitor: effects on fetal and neonatal outcomes. Reprod Toxicol. 2008;26(2):175–177.
42.
WoollettLA. Maternal cholesterol in fetal development: transport of cholesterol from the maternal to the fetal circulation. Am J Clin Nutr. 2005;82(6):1155–1161.
